Pro-Avandia FDA Panelist Is Paid GSK Speaker

Law360, New York (July 20, 2010, 3:02 PM EDT) -- One of the U.S. Food and Drug Administration's advisory panelists who voted to keep the controversial diabetes drug Avandia on the market reportedly is also a paid speaker for the manufacturer, GlaxoSmithKline PLC.

Dr. David Capuzzi, an endocrinologist from Philadelphia, confirmed that he had been on GSK's speakers bureau for several years but does not see the role as a conflict with his regulatory duties, according to a Wall Street Journal report Tuesday.

“I have not given any talks [to doctors groups] promoting Avandia,” he told...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.